Acute Myeloid Leukemia

Newly Diagnosed

Unfit

HEMAML0046
Phase I ASTX727 in Combination with Venetoclax in Acute Myeloid Leukemia
PI: Mannis
Astex Pharmaceuticals
Cohort 3

Priority 1

HEMAML0047
Phase 1B CC-486 (ONUREG®) in Combination Therapy in Acute Myeloid Leukemia (AML)
PI: Zhang
Celgene Corporation

Priority 2

HEMAML0044
Feasibility of Telehealth-Based Palliative Care Intervention & Digital Symptom Monitoring in AML
PI: Mannis
Stanford

Fit

HEMAML0043
Phase 1 CPX-351 + Various Targeted Agents in Previously Untreated Acute Myeloid Leukemia
PI: Mannis
Jazz Pharmaceuticals

HEMAML0059
Phase III IMGN632 Monotherapy Administered Intravenously in CD123-Positive Acute Myeloid Leukemia & Other CD123-Positive Hematologic Malignancies
PI: Mannis
ImmunoGen, Inc.

Blastic Plasmacytoid Dendritic Cell Neoplasm

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu